Key result
Lipid-lowering therapies offer promising dyslipidemia control but face major cost, access, and adherence hurdles.
Recent advancements in lipid-lowering therapies provide promising treatment options, though challenges remain regarding cost, accessibility, and the need for personalized medicine.
Lipid metabolism is a well-regulated process essential for maintaining cellular functions and energy homeostasis. Dysregulation of lipid metabolism is associated with various conditions, including cardiovascular diseases, neurodegenerative disorders, and metabolic syndromes. This review explores the mechanisms underlying lipid metabolism, emphasizing the roles of key lipid species such as triglycerides, phospholipids, sphingolipids, and sterols in cellular physiology and pathophysiology. It also examines the genetic and environmental factors contributing to lipid dysregulation and the challenges of diagnosing and managing lipid-related disorders. Recent advancements in lipid-lowering therapies, including PCSK9 inhibitors, ezetimibe, bempedoic acid, and olpasiran, provide promising treatment options. However, these advancements are accompanied by challenges related to cost, accessibility, and patient adherence. The review highlights the need for personalized medicine approaches to address the interplay between genetics and environmental factors in lipid metabolism. As lipidomics and advanced diagnostic tools continue to progress, a deeper understanding of lipid-related disorders could pave the way for more effective therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Dakal et al. (2025) conducted a review in Lipid dysregulation. Lipid-lowering therapies provide promising treatment options for lipid dysregulation, though their use is accompanied by challenges related to cost, accessibility, and patient adherence.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: